Enasidenib as treatment for AML with IDH2 mutation: multicenter real-life study of the early-access program in Spain

1. Jiménez-Vicente,C.
2. Beneit,P.
3. Cano-Ferri,I.
4. Merchán,B.
5. Arnan,M.
6. Guiñón,A.G.
7. Martínez-Bilbao,C.
8. Alfonso,A.
9. Martínez-Sánchez,P.
10. Alonso-Domínguez,J.M.
11. López-Godino,O.
12. Castaño-Díez,S.
13. Zugasti,I.
14. Esteve,J.
15. Díaz-Beyá,M.
16. de la Fuente,A.

Export

Export ×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export ×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1007/S00277-025-06464-1 GOOGLE SCHOLAR lock_openOpen access editor

Data source: Scopus